Key result
The FDA approved the thienopyridine prasugrel for use in patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
The FDA approved prasugrel in 2009 for patients with unstable angina or myocardial infarction undergoing PCI.
On July 10, 2009, after an 18-month review, the Food and Drug Administration (FDA) approved the thienopyridine prasugrel for use in patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention (PCI). The new drug is the latest addition to a class of agents that inhibit the platelet adenosine diphosphate (ADP) receptor, preventing initial platelet activation and consequent platelet aggregation — a mechanism that has represented a major advance in the treatment of atherothrombotic diseases.1 Indeed, the use of the thienopyridine ticlopidine in combination with aspirin to inhibit platelet aggregation facilitated the widespread use of coronary-artery stenting. Because . . .
No takes yet. Share an insight, caveat, or question.
Deepak L. Bhatt (2009) conducted an editorial in Unstable angina or myocardial infarction undergoing PCI. Prasugrel was evaluated. The FDA approved the thienopyridine prasugrel for use in patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: